Tuberculosis R&D funding is up, but still short of goals, report finds

Taking stock of the drug industry, from the lab to the medicine chest

December 13, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Tuberculosis R&D funding is up, but still short of goals and dominated by a few players, report finds The report found that the U.S. National Institutes of Health and the Bill & Melinda Gates Foundation contributed 53% of all R&D TB funds. By Ed Silverman STAT+ | For a leukemia that keeps returning, AbbVie drug may offer chance for a deep remission Most patients with chronic lymphocytic leukemia eventually relapse. A bispecific antibody drug may give them "another can to kick." By Angus Chen STAT+ | Ionis blazed trails in genetic medicine. On the cusp of a major approval, can it also be a commercial success? For more than 30 years, Ionis developed medicines in partnership with Big Pharma. This time, it is standing alone By Jonathan Wosen and Matthew Herper Courtesy Opinion: I have a rare form of ALS. I have to fight my insurance company every six months for a game-changing drug I am once again at the mercy of an insurance system that treats human life as just another line on a balance sheet. By Shelby Kinsey

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser